Effects on prognosis of hematologic parameters in patients with small cell lung cancer
Abstract
Purpose: The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are prognostic factors for various types of cancer. In this study, we assessed the association of NLR and PLR with the prognosis of small-cell lung cancer (SCLC) in patients who received the standard treatment.
Material and Methods: We retrospectively reviewed patients who were diagnosed with SCLC and treated with the standard chemotherapy at Suleyman Demirel University Chest Diseases and Dr. Suat Seren Chest Diseases and Thoracic Surgery.
Results: In total, 136 patients were evaluated. Patients’ clinic characteristics and hematologic tests data at initial diagnosis were collected. The univariate analysis of all SCLC patients indicated that favorable prognostic factors were gender, disease stage, the number of metastatic sites, good performance status and received treatment according to the stage. Moreover, univariate analysis showed that low lymphocyte count (<1590) and high neutrophil-lymphocyte ratio (≥3.7) predicted poor prognosis in SCLC. Median overall survival (OS) was worse in the high-NLR group. In the multivariate analysis, NLR, stage, the number of metastatic sites, karnofsky performance status (KPS), received treatment were independent prognostic factors for OS.
Conclusion: This study demonstrated that the NLR could help to predict poor prognosis in SCLC patients before treatment. Larger prospective studies are required to confirm these findings.
Keywords
Kaynakça
- Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539-44.
- Dowell JE. Small cell lung cancer: are we making progress? Am J Med Sci. 2010;339:68-76.
- National Cancer Institute at National Institutes of Health. Small cell lung cancer Treatment for health professionals 2015; PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-2015 Jan 23.
- Buccheri G, Ferrigno D. Prognostic factors of small cell lung cancer. Hematol Oncol Clin North Am. 2004;18:445–60.
- Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89:523–33.
- Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer. 2003;39:303-13.
- Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol.
- Mantovani A. Cancer: inflaming metastasis. Nature. 2009;1(457):36-7.
- Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565-70 .
- Lee S, Oh SY, Kim SH, Lee JH, Kim, MC, Kim KH et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer. 2013;22:350.
